Abstract
rearrangement events compared with normal cells (Fig. 1c, Supplementary Fig. 1 ).
159

Detection and Characterization of Translocations and Large Scale Re--arrangements
160
It has been suggested that strong inter--chromosomal interactions observed in Hi--C designed an iterative refinement algorithm to systematically detect translocations in cancer 166 genomes using Hi--C data (details in method section, Supplementary Fig. 2 ). translocations and intra--chromosomal re--arrangements (Fig. 2a,b) . Sanger sequencing ( Supplementary Fig. 4 ).
202
To further evaluate the sensitivity of our approach, we evaluated its ability to detect depth and method used to call overlap, and appears to plateau when using 100 million 212 sequencing read pairs or more ( Supplementary Fig. 5b ). In addition, we observe high 213 internal consistency of breakpoints calls when there is at least 50 million reads
214
( Supplementary Fig. 5c,d ). This result suggests that our method requires only modest 215 sequencing depths to achieve high sensitivity and saturation of breakpoint calls, and that we 216 can achieve decent sensitivity with as little as 5--10 million reads. By examining the "missed" 217 breakpoints, we observe that Hi--C may call breakpoints in identical regions as identified by
218
WGS, but identifies a different strand as part of the breakpoint ( Supplementary Fig. 5e,f) .
219
This suggests that although Hi--C does not always precisely resolve the strandedness of a Table 7 ).
234
We observed that 25% of these rearrangements were identified by more than one restriction enzymes or nickases that recognize target motifs with a spacing greater than 1kb
244
(Hi--C) and 10Kb (optical mapping), small SVs are unlikely to be captured by these methods.
245
On the other hand, both Hi--C and optical mapping can identify rearrangements in repetitive Supplementary Fig. 6h ). Finally, we observed that both Hi--C and Irys are particularly 255 powerful at detecting complex translocation events, as illustrated in Supplementary Fig. 3 .
256
In summary, these results illustrate that each method has unique strengths and weaknesses,
257
and should be applied accordingly depending on the study goals. Whenever possible, an 258 integrative approach of different methods is essential to gain a more complete knowledge 259 of structural variation in cancer genomes.
260
Validation of breakpoints using replication timing based on the replication timing of the loci. However, the lack of a control cell line that
275
represents the pre--translocation replication timing of the loci confounds this classification.
276
To circumvent this problem, we classified the genome into regions that are constitutively were CE to CE or CL to CL fusions. As expected, an abrupt shift in timing was identified in CE
282
to CL with a much higher frequency (~59%) than in CE to CE or CL to CL fusions tissue--specific and cancer type--specific genes and pathways (Fig. 3f, g) were also amplified in T47D cancer cells, and tumor suppressor genes such as ATRX and
366
CDKN1B displayed loss of copies (Fig. 4a) , suggesting that T47D cells reflect the CNV 367 landscape in breast cancer and our method can accurately capture these variations. We ( Supplementary Fig. 10a,b ) . We found deletions in exonic regions of a total of 25 COSMIC 374 tumor--related genes, and the majority (76%) showed decreased transcription
375
( Supplementary Fig. 10c ). We made similar observations when comparing transcriptomes in 376 other cancer cells (Supplementary Fig. 10d ). These results suggest that our integrated Supplementary Fig. 11 ). In addition, we found over 100 genes that are extensively amplified 381 or deleted in cancer cells but were not reported in COSMIC, suggesting their potential roles 382 in cancer (Supplementary Fig. 12 ).
383
Disruption of non--coding elements in cancer genomes
384
We are also interested in whether structural variants can affect non--coding regulatory 385 elements and whether such alterations play a role in oncogenesis. For this analysis, we 386 focused on comparing the enhancer landscape in T47D breast cancer cells and HMEC cells.
387
We downloaded histone modification data from both cell types from the ENCODE Ontology analysis with the GREAT tool. Strikingly, we found that these deleted enhancers of 400 T47D are located near genes important for cellular response to VEGF, genes down--regulated 401 in breast cancer, and genes involved in abnormality of DNA repair (Fig. 4d) genomic re--arrangements in cancer cells (Fig. 5a,b) . For example, we identified a 421 translocation from chr7 to chr8 in SK--N--SH cells (Fig. 5a ). The breakpoint region on n--myc, SK--N--SH cells are a rare sub--type that express high levels of c--myc but not n--myc 59 .
425
In examining the 3D genome structure near this re--arrangement, we observed extensive breakpoints in all cell lines (Fig. 5c ). We observed that on average, the nearest "normal"
432
TAD boundaries appear to be fused together on each side of the breakpoint creating neo-- Genes with homozygous deletion and LOH in T47D show reduced expression (p=0.009, p=0.003), and genes with gain of copies increased expression (p=4×10 -79 ), relative to the expression in HMEC cells. c. A 130Kb deletion in T47D contains a cluster of distal regulatory elements, three of which are linked with ERBB4 gene by Capture Hi-C. d. The deleted enhancers are located near genes important for pathways related to breast cancer. e. Genes with deleted enhancers show reduced expression levels. We only used gene without exon deletion or copy number loss in this analysis. Then we put genes into two groups: 534 genes with loss of at least one linked enhancers indicated by Capture Hi-C; 10677 without deletion of linked enhancer. The boxplot shows the absolute value of these -scores. Gene located in TA s containing re-arrangements tend to have higher absolute value of their -scores, indica�ng more variable expression pa erns. e. Model for neo-TA forma�on. Na�ve TA structures are re-arranged as the result of breaks and fusions, resul�ng in the uxtaposi�on of regulatory se uences from one domain and genes from another, poten�ally altering the regulatory landscape of cancer genomes.
